Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1391&sort=award_amount
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=award_amount", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=award_amount", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=award_amount", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1390&sort=award_amount" }, "data": [ { "type": "Grant", "id": "3743", "attributes": { "award_id": "1638352", "title": "Research in Mathematics", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Mathematical and Physical Sciences (MPS)", "MATHEMATICAL SCIENCES RES INST" ], "program_reference_codes": [], "program_officials": [ { "id": 12236, "first_name": "Marian", "last_name": "Bocea", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-01", "end_date": "2021-08-31", "award_amount": 7998750, "principal_investigator": { "id": 12238, "first_name": "Helmut", "last_name": "Hofer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 12237, "first_name": "Peter", "last_name": "Sarnak", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 892, "ror": "https://ror.org/00f809463", "name": "Institute for Advanced Study", "address": "", "city": "", "state": "NJ", "zip": "", "country": "United States", "approved": true }, "abstract": "The School of Mathematics (SoM) at the Institute for Advanced Study (IAS) has two primary goals. First, it supports fundamental research in mathematics, encourages original thinking, and produces significant advances in knowledge. Second, it invests in the development of a diverse pool of mathematical talent. The School strongly encourages the participation of women and members of other groups underrepresented in mathematics, and is dedicated to furthering the education and careers of all of its postdoctoral fellows. Junior mathematicians benefit from both their interactions with senior scholars and the mentoring they receive from faculty members. Mid-career and senior mathematicians consolidate their research projects and explore new research directions. The School's emphasis on a unified, interdisciplinary mathematical perspective and its work in bringing together a diverse group of mathematicians has led to numerous unanticipated mathematical developments. The School is in a strong position to identify, at an early stage, subject areas with the potential for important new developments. The School is led by eight permanent faculty members whose expertise span a wide spectrum of mathematics. As a center for new collaborations and new lines of research, the School hosts approximately 75 visiting mathematicians annually whose collaborative research visits typically last 4-10 months. This grant supports 23 of these scholars (17 postdoctoral fellows and 6 mid-career mathematicians), who join approximately 50 other mathematicians supported by funds from other sources. It also provides funds to host small groups of collaborators during the summer.\n\nThe School of Mathematics provides this diverse community of scholars with an interactive environment, rich in mathematical content and conducive to collaboration. Each year SoM conducts a special program focused on a particularly exciting field of mathematics. The programs for the next three years will be \"Locally Symmetric Spaces: Analytical and Topological Aspects\" in 2017-2018; \"Variational Methods in Geometry\" in 2018-2019; and \"Optimization, Statistics, and Theoretical Machine Learning\" in 2019-2020. Each semester SoM facilitates a week-long workshop associated with the special topical program, as well as a separate week-long working group. The \"Emerging Topics Working Group\" is a group of researchers selected to work on a topic which seems ripe for significant progress. Other programs include \"Mathematical Conversations,\" an informal discussion group that meets once a week, and \"Summer Collaborators,\" small groups of invited researchers who collaborate on special research projects during the summer months. In addition to these workshops and programs, the SoM offers regular seminars, lecture series, and reading groups. All IAS lectures are videotaped and are available to the public. Visiting mathematicians supported by the grant receive individual and group mentoring from the permanent faculty members. Their individual research projects dive into one or more of the following fields of study: Analysis, Partial Differential Equations of Applied Mathematics, Probability, Algebra, Algebraic Geometry, Lie Groups, Representation Theory, Differential Geometry, Topology, Mathematical Physics, Dynamical Systems, Computer Science, Discrete Mathematics, Theoretical Machine Learning, and Number Theory.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "12394", "attributes": { "award_id": "1C06OD036038-01", "title": "Further expansion of the Southwest National Primate Research Center Specific Pathogen Free Rhesus Macaque Resource", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 11602, "first_name": "GUANGHU", "last_name": "Wang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2023-09-08", "end_date": "2027-04-30", "award_amount": 8000000, "principal_investigator": { "id": 23354, "first_name": "JOANNE", "last_name": "TURNER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1083, "ror": "https://ror.org/00wbskb04", "name": "Texas Biomedical Research Institute", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1083, "ror": "https://ror.org/00wbskb04", "name": "Texas Biomedical Research Institute", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "The Southwest National Primate Research Center (SNPRC) houses a Specific Pathogen Free (SPF) rhesus macaque colony of Indian origin (Ind RM), supported by the NIH SPF rhesus breeding program (U42OD010442), and a smaller SPF P51 supported colony. We currently house ~1000 rhesus macaques, of which the U42 colony of approximately 800 animals supports AIDS-related research both at SNPRC and through sales to AIDS investigators at other institutions. However, there is a major national shortage of research nonhuman primates (NHPs), and particularly of SPF Ind RM. This has severely impacted our ability to support the national and international research mission of HIV/AIDS as well as in the area of non-AIDS/other infectious diseases, AIDS co-infections, malaria, TB, COVID-19, etc. The NIH has recognized this need for expansion of SPF rhesus production and strongly recommends increasing Ind RM breeding capacity. The SNPRC is well positioned to expand its SPF Ind RM production as a center located in a climate hospitable to largely outdoor housing, at an institution with capacity for expansion. Our host institution, Texas Biomed, raised funds and is currently building new NHP facilities which will house ~600 NHPs. Texas Biomed/SNPRC has also been funded by the NIH/ORIP to expand our production capacity by 30% over our existing capacity via other mechanisms. Finally, through Texas Biomed support, we have procured ~150 conventional founder/breeder Ind RM. This founder colony has increased the number of breeding pairs the SNPRC macaque colony management team can generate, and it is expected that in the upcoming birthing season, ~200 RM live births will occur, double that of each of the last several years. As such the SNPRC Ind RM population can increase to 1500+ in the next five years. Funded partially by this C06, we seek to construct an additional animal housing/breeding facility adjacent the two new holding/breeding facilities currently under construction, as part of the overall $45M long term Animal Care Complex project. This will further allow us to house, breed and maintain an additional supply of ~300 Ind RM for AIDS/emerging infectious diseases research.", "keywords": [ "Acquired Immunodeficiency Syndrome", "Animal Housing", "Animals", "Area", "Breeding", "COVID-19", "Climate", "Communicable Diseases", "Complex", "Emerging Communicable Diseases", "Fund Raising", "Funding", "HIV/AIDS", "Housing", "Infectious Diseases Research", "Institution", "International", "Live Birth", "Macaca", "Macaca mulatta", "Malaria", "Mission", "Population", "Positioning Attribute", "Primates", "Production", "Recommendation", "Research", "Research Personnel", "Resources", "Rhesus", "Sales", "Texas", "United States National Institutes of Health", "animal care", "co-infection", "germ free condition", "nonhuman primate", "programs", "season of birth" ], "approved": true } }, { "type": "Grant", "id": "4577", "attributes": { "award_id": "1522054", "title": "Collaborative Research: CompSustNet: Expanding the Horizons of Computational Sustainability", "funder": { "id": 3, "ror": "https://ror.org/021nxhr62", "name": "National Science Foundation", "approved": true }, "funder_divisions": [ "Computer and Information Science and Engineering (CISE)", "Expeditions in Computing" ], "program_reference_codes": [], "program_officials": [ { "id": 15790, "first_name": "Sylvia", "last_name": "Spengler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2015-12-15", "end_date": "2023-11-30", "award_amount": 8060000, "principal_investigator": { "id": 15795, "first_name": "Carla", "last_name": "Gomes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 279, "ror": "https://ror.org/05bnh6r87", "name": "Cornell University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 15791, "first_name": "Jon M", "last_name": "Conrad", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 15792, "first_name": "John E", "last_name": "Hopcroft", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 15793, "first_name": "David B", "last_name": "Shmoys", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 15794, "first_name": "Bart", "last_name": "Selman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 279, "ror": "https://ror.org/05bnh6r87", "name": "Cornell University", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Poverty, saving species, repowering the world with renewable energy, lifting people up to live better lives - there are no easy answers to guiding our planet on the path toward sustainability. Complex problems require sophisticated solutions. They involve intricacy beyond human capabilities, the kind of big-data processing and analysis that only advanced large-scale computing can provide. This NSF Expedition in Computing launches CompSustNet (http://www.compsust.net), a vast research network powered by the nation's recognized university computer science programs, charged with applying the emerging field of computational sustainability to solving the world's seemingly unsolvable resource problems. Put simply, the project will enlist some of the top talents in computing, social science, conservation, physics, materials science, and engineering to unlock sustainable solutions that safeguard our planet's future.\n\nComputational Sustainability is, at its core, the belief that with sufficiently advanced computational techniques, we can devise sustainable solutions that meet the environmental, societal, and economic needs of today while providing for future generations. In much the same way IBM's supercomputer Watson could defeat any challenger in Jeopardy!, computational sustainability posits that a computer-engineered solution can be applied to world's difficult and challenging problems - from helping farmers and herders in Africa survive severe droughts to developing a smart power grid fueled entirely by renewable energy. CompSustNet is a large national and international multi-institutional research network led by Cornell University and including 11 other US academic institutions: Bowdoin, Caltech, CMU, Georgia Tech, Howard University, Oregon State, Princeton, Stanford, UMass, University of South California, and Vanderbilt University, as well as collaborations with several international universities. But CompSustNet is not just an academic enterprise, as it also includes key governmental and non-governmental organizations that specialize in conservation, poverty mitigation, and renewable energy, such as The Nature Conservancy, The World Wildlife Fund, The International Livestock Research Institute, The Trans-African Hydro-Meteorological Observatory, and the National Institute of Standards and Technology.\n\nCompSustNet's core mission is to significantly expand the horizons of computational sustainability and foster the advancement of state-of-the-art computer science to achieve the scale to tackle global problems. Research will focus on cross-cutting computational topics such as optimization, dynamical models, simulation, big data, machine learning, and citizen science, applied to sustainability challenges. For example, computational sustainability is being put to work to resolve the problem of providing wetlands for shorebirds that migrate from the Arctic through California during a time of drought. As California gets drier, the shorebirds have nowhere to stop, rest, and refuel by eating wetland invertebrates. Scientists are developing new dynamic precision conservation techniques that use complex, big-data models to tackle the problem with NASA satellite imagery, meteorological forecasts, and citizen science in the form of thousands of bird location sightings from the Cornell Lab of Ornithology's eBird checklisting app for birdwatchers. Through partnership with The Nature Conservancy, the program forecasts when and where wetland habitat would be needed for shorebirds, and the Conservancy pays Central Valley rice farmers to flood their fields at opportune times - providing benefits for birds and farmers at a time when extreme drought is making life tough for both. In similar ways, computational sustainability projects will also be hard at work innovating automated monitoring networks to protect endangered elephant population from poachers, promoting the discovery of novel ways to harvest energy from sun light, and designing algorithms to manage the generation and storage of renewable energy in the power grid. \n\nAdvancements in computational sustainability will lead to novel, low-cost, high-efficiency strategies for saving endangered species, helping indigenous peoples improve their way of life, and scaling renewables up to meet 21st century energy demand. CompSustNet is like the seed, the venture capital, to help the field of computational sustainability achieve what's possible.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8156", "attributes": { "award_id": "75N92021C00012-0-9999-1", "title": "AWARD A CONTRACT FOR RADX TECH - CERES TO DEVELOP A WASTEWATER COVID-19 SURVEILLANCE FRAMEWORK DRIVEN BY PUBLIC HEALTH AUTHORITIES AT CITY, COUNTY AND", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-04-16", "end_date": "2022-04-15", "award_amount": 8200000, "principal_investigator": { "id": 24014, "first_name": "ROSS", "last_name": "DUNLAP", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1155, "ror": "", "name": "CERES NANOSCIENCES, LLLP", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1155, "ror": "", "name": "CERES NANOSCIENCES, LLLP", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "Ceres Nanosciences, developer of Nanotrap particles for extracting and concentrating SARS-CoV-2, have successfully validated the use of these particles in multiple laboratories and contexts to capture and concentrate SARS-CoV-2 from biological solutions or wastewater at levels currently below the limit of detection of existing methods. This has attracted the interest of over 15 commercial partners, such as LabCorp, who are leading the national efforts to provide diagnostic tests for COVID-19 infection. The cumulative needs for these partners are tests in excess of 2,000,000/day. Our current manufacturing processes are not able to meet this demand and represent a bottleneck to helping to address the national crisis. As such, Ceres Nanosciences is requesting RADx support to rapidly scale-up Nanotrap manufacturing and distribution under our existing quality management system to meet the demand of partners, such as LabCorp, who are poised to leverage the technology for point-of-care and confirmatory testing for COVID-19 infection. EUA amendment data collection and supply contract agreements are in process.", "keywords": [ "2019-nCoV", "Address", "Agreement", "Amendment", "Biological", "COVID-19 surveillance", "COVID-19 testing", "Cities", "Contracts", "County", "Data Collection", "Diagnostic tests", "Laboratories", "Methods", "Point of Care Technology", "Process", "Public Health", "RADx", "RADx Tech", "SARS-CoV-2 infection", "System", "Testing", "authority", "detection limit", "interest", "manufacturing process", "nanoscience", "particle", "scale up" ], "approved": true } }, { "type": "Grant", "id": "10477", "attributes": { "award_id": "75N95021D00001-0-759502200008-1", "title": "STSS PROGRAM SUPPORT & STSS COVID-19 EMERGENCY RESPONSE SUPPORT", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Center for Advancing Translational Sciences (NCATS)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2022-05-09", "end_date": "2022-08-15", "award_amount": 8237623, "principal_investigator": { "id": 26488, "first_name": "GARY", "last_name": "MAYS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1701, "ror": "", "name": "AXLE INFORMATICS, LLC", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "National COVID-19 Cohort Collaborative (N3C): The National COVID-19 Cohort Collaborative (N3C) sponsors the NIH COVID-19 Data Enclave, https://covid.cd2h.org/, one of the largest data enclaves in the world supporting COVID-19 research. N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs, the National Center for Data to Health (CD2H), and the NIGMS-supported Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR), with overall stewardship by NCATS. The N3C program is essentially a medium sized business, consisting of thousands of researchers, requiring enterprise level information technology (IT) support as part of a virtual research organization (VRO). This contract is necessary to ensure that NCATS and N3C can continue to provide adequate support for a secure, collaborative, VRO. This contract allows for continued support of the VRO which supports all of the required information technology functions to support an environment of over 4,000 users, including cloud-based productivity tools, a service desk, commercial and open-source deployments of analytical tools for the community to use, and expansion of the data types available for analysis, such as imaging, viral variant genomic sequences, etc. The common need is to share a collaborative cloud environment capable of ingesting billions of data points and performing a variety of complex analyses against multimodal data types, ranging from pathology and radiology data, synthetic data, genomic information, electronic health records (EHRs) and a wide variety of others. All of this must be done while meeting the highest levels of security and privacy, given the sensitivity of some of the data types being collected and the importance of the work being done in the environment. This contract provides support for all of these enterprise IT efforts.", "keywords": [ "Area", "Award", "Businesses", "COVID-19", "COVID-19 patient", "Clinical Research", "Clinical and Translational Science Awards", "Collaborations", "Communities", "Complex Analysis", "Contracts", "Data", "Data Analyses", "Data Collection", "Data Science", "Data Set", "Development", "Electronic Health Record", "Emergency response", "Ensure", "Environment", "Genomics", "Health", "Image", "Informatics", "Information Technology", "Ingestion", "National Center for Advancing Translational Sciences", "National Institute of General Medical Sciences", "Pathology", "Privacy", "Productivity", "Pythons", "Radiology Specialty", "Research", "Research Personnel", "Risk Factors", "Scientist", "Secure", "Security", "Services", "Statistical Data Interpretation", "Translational Research", "United States", "United States National Institutes of Health", "Viral", "Visualization", "Work", "analytical tool", "cloud based", "cohort", "coronavirus disease", "data enclave", "data harmonization", "genetic variant", "meetings", "multimodal data", "open source", "open source tool", "programs", "protective factors", "tool", "virtual" ], "approved": true } }, { "type": "Grant", "id": "12419", "attributes": { "award_id": "75N93023C00052-0-9999-1", "title": "DEVELOPMENT OF A COMPOUND FOR THE TREATMENT OF COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2023-09-22", "end_date": "2026-02-15", "award_amount": 8469477, "principal_investigator": { "id": 28367, "first_name": "", "last_name": "", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2101, "ror": "", "name": "ALIGOS THERAPEUTICS, INC.", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "To support the advanced development of a promising antiviral against a pathogen with pandemic potential. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.", "keywords": [ "Advanced Development", "COVID-19 therapeutics", "COVID-19 treatment", "Chemistry", "Clinical", "Development", "Pathway interactions", "Viral", "efficacy evaluation", "manufacture", "pandemic potential", "pathogen", "pre-clinical", "product development", "research and development", "safety assessment", "therapeutic candidate" ], "approved": true } }, { "type": "Grant", "id": "9141", "attributes": { "award_id": "75N92020C00009-P00002-9999-1", "title": "RADX PROGRAM: TECH PROJECT NO 6114 FLUIDIGM ADVANTA DX SARS-COV-2 RT-PCR ASSAY FOR SALIVA", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-07-30", "end_date": "2021-09-30", "award_amount": 8580056, "principal_investigator": { "id": 24916, "first_name": "ANDREW", "last_name": "QUONG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1801, "ror": "", "name": "FLUIDIGM CORPORATION", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1801, "ror": "", "name": "FLUIDIGM CORPORATION", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Fluidigm's BioMark HD microfluidics platform addresses the massive demand for SARS-CoV-2 PCR testing- combining speed, minimal cost, and massive throughput unparalleled in the industry. Further advantages include flexibility to rapidly integrate new mutational markers or increase panel size to include additional infectious agents. This platform works with all clinical sample types. 1) Technology Development Our solution leverages Advantaâ„¢ Dx SARS-CoV-2 RT-PCR Assay submitted for an EUA, and two assays under development that can change the landscape for detection. This assay allows for up to 6000 samples per day on a single system. Additional assays address different needs in testing, throughput, specificity and sensitivity. Modifications to the current workflow increases throughput to 48,000 tests per day while maintaining the identity of each sample. To distinguish between SARS-CoV-2 infection and other respiratory viruses, we will deploy our multiplexed capability to create a pan-respiratory panel. Cost estimates are preliminary based on assumptions of volume and distribution model. To enable pre-symptomatic screening, we are working with the DARPA ECHO program on a host response signature that can be run on the same platform. 2) Scaleup In three months our goal is to scale up manufacturing to over one million tests per day delivering 80 million tests by end of year. Investments in incremental capacity will deliver a cumulative run rate of 4.5 million tests per day in mid 2021. These two components provide a robust platform for scale up of testing for SARS-CoV-2 that allows for the simultaneous detection of other respiratory pathogens.", "keywords": [ "2019-nCoV", "Address", "Biological Assay", "COVID-19 testing", "Clinical", "Detection", "Development", "Goals", "Immune response", "Industry", "Infectious Agent", "Investments", "Microfluidics", "Modeling", "Modification", "Mutation", "RADx", "Reverse Transcriptase Polymerase Chain Reaction", "Running", "SARS-CoV-2 infection", "Sampling", "Sensitivity and Specificity", "Speed", "System", "Testing", "Work", "base", "cost", "cost estimate", "flexibility", "manufacturing scale-up", "programs", "respiratory", "respiratory pathogen", "respiratory virus", "salivary assay", "scale up", "screening", "technology development" ], "approved": true } }, { "type": "Grant", "id": "5096", "attributes": { "award_id": "3UM1AI068618-17S1", "title": "CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection LC 3", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 18177, "first_name": "Patricia D.", "last_name": "D'Souza", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2006-06-29", "end_date": "2027-11-30", "award_amount": 8696751, "principal_investigator": { "id": 18178, "first_name": "Margaret Juliana", "last_name": "McElrath", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 758, "ror": "https://ror.org/007ps6h72", "name": "Fred Hutchinson Cancer Center", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "This proposal outlines the scientific agenda for the COVID-19 Prevention Network (CoVPN) Vaccines Leadership Operations Center (LOC) for implementation of a natural history trial for acute SARS-CoV-2 infection in hospitalized and non-hospitalized individuals: “A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection.” With the onset of the COVID-19 pandemic, we recognize there is a significant gap in knowledge in the field on the contribution of innate and adaptive immune functions in modifying COVID-19 disease and in clearing viral infection and in the ability of vaccines to prevent or modify COVID-19 disease in SARS-CoV-2 infected individuals. Addressing this gap, the National Institute of Health (NIH) led rapid constitution of the CoVPN, partnering 5 NIH supported clinical trial networks, to create an enhanced network of physician scientists at 64 United States (US) and 55 international clinical trial sites in 15 countries dedicated to developing globally effective vaccines for SARS-CoV-2. Due to its extensive experience implementing global HIV vaccine trials over the last 20 years, the HIV Vaccine Trials Network (HVTN) LOC was selected as the LOC for CoVPN vaccine trials. We believe the CoVPN is well placed to study the natural history gaps and rapidly deploy this information in the development of SARS-CoV-2 neutralizing vaccines and mAb therapies. In this study we propose initiating an observational cohort study of approximately 950 acutely infected persons recruited at 17 United States (US) and 43 international clinical trial sites over an 8 month period. Adults 18 years and older with RT-PCR positive SARS-CoV-2 test results will be enrolled competitively across trial sites until the full cohort is reached. Participants will follow up for 6 clinic visits over a 28 day period and receive a final remote contact one month after the last visit. Participants who experience clinical decompensation will be referred for hospital evaluation. Specific aims of the study are to generate standardized datasets characterizing the SARS-CoV-2 viral kinetics and the quality, magnitude, and kinetics of humoral, innate and cellular immune responses to SARS-CoV-2 infection in asymptomatic and acutely symptomatic participants (in both hospitalized and non-hospitalized individuals) from a diversity of geographic and genetic backgrounds. This natural history study will tell us much about the adaptive immune responses in persons who are acutely infected from SARS-CoV-2 and will shed light on the role the immune system plays in successfully clearance of infection. It will improve our understanding of the dynamics and duration of responses against variants of concern, including Omicron, as well as the epitope specificity and other defining signatures, and will inform rational design and testing of preventive and therapeutic vaccines and monoclonal antibodies. Lastly, this study will inform the network on critical issues associated with implementation of current and future COVID-19 vaccine trials.", "keywords": [ "2019-nCoV", "Acute", "Address", "Adult", "Biological Assay", "Biometry", "COVID-19", "COVID-19 Prevention Network", "COVID-19 outbreak", "COVID-19 pandemic", "COVID-19 test", "COVID-19 vaccine", "Cellular Assay", "Clinic Visits", "Clinical", "Clinical Trials", "Clinical Trials Network", "Cohort Studies", "Communicable Diseases", "Constitution", "Country", "Data Set", "Development", "Disease", "Enrollment", "Epitopes", "Evaluation", "Eye", "Future", "Genetic", "Geography", "Goals", "HIV Vaccine Trials Network", "HIV vaccine", "Health", "Hospitals", "Immune", "Immune response", "Immune system", "Immunity", "Immunology", "Individual", "Infection", "Infection Control", "International", "Kinetics", "Knowledge", "Laboratories", "Lead", "Leadership", "Light", "Malaria", "Mediating", "Monoclonal Antibodies", "Monoclonal Antibody Therapy", "Morbidity - disease rate", "Natural History", "Outcome", "Participant", "Persons", "Phase", "Physicians", "Play", "Population", "Population Heterogeneity", "Preparation", "Prevention", "Prevention strategy", "Preventive vaccine", "Prospective Studies", "Protocols documentation", "Quality Control", "Randomized Clinical Trials", "Research Methodology", "Reverse Transcriptase Polymerase Chain Reaction", "Risk", "Role", "SARS-CoV-2 infection", "SARS-CoV-2 positive", "Sampling", "Scientist", "Serology test", "Site", "Specificity", "Standardization", "System", "Test Result", "Testing", "Typhoid Fever", "United States", "United States National Institutes of Health", "Vaccine Therapy", "Vaccines", "Validation", "Viral", "Virus Diseases", "Visit", "adaptive immune response", "base", "clinical trial analysis", "cohort", "design", "efficacy study", "efficacy trial", "experience", "follow-up", "immune function", "improved", "mortality", "neutralizing vaccine", "operation", "pandemic disease", "prevent", "programs", "quality assurance", "recruit", "response", "therapeutic vaccine", "vaccine trial", "vaccine-induced antibodies", "variants of concern" ], "approved": true } }, { "type": "Grant", "id": "9252", "attributes": { "award_id": "75N91019D00024-P00001-759102000025-3", "title": "International study on COVID-19 Vaccine to assess Immunogenicity, Reactogenicity and Efficacy (InVITE)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-09-28", "end_date": "2025-09-27", "award_amount": 8758469, "principal_investigator": { "id": 24984, "first_name": "SALLY", "last_name": "HUNSBERGER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "This funding supports a multicenter study of COVID-19 vaccine immunogenicity and durability, and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections in people who receive a COVID-19 vaccine through their country’s national vaccination programs. The study will be conducted in international sites including those that participate in the Division of Clinical Research Special Projects. This study is unique in that it examines the immunogenicity of multiple different vaccination regimens (both initial and booster) across several countries.", "keywords": [ "2019-nCoV", "Age", "Antibody Response", "Body mass index", "COVID-19 vaccine", "Clinical Research", "Country", "Data", "Funding", "HIV Infections", "Immunization Programs", "Infection", "International", "Measures", "Multicenter Studies", "Participant", "Regimen", "SARS-CoV-2 infection", "Site", "Subgroup", "Vaccination", "Vaccines", "Virus", "comorbidity", "immunogenicity", "study population", "viral genomics" ], "approved": true } }, { "type": "Grant", "id": "8089", "attributes": { "award_id": "75N92021C00001-0-9999-1", "title": "TO UPDATE THE PERFORMANCE WORK STATEMENT FOR RADX TECH PROJECT NO. 2643 - PATHOGENDX, INC. - PATHOGENDX COVID-19 MICROARRAY CLADE VARIANT DETECTION TE", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2021-02-22", "end_date": "2022-02-21", "award_amount": 8919208, "principal_investigator": { "id": 23976, "first_name": "MILAN", "last_name": "PATEL", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1095, "ror": "", "name": "PATHOGENDX", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1095, "ror": "", "name": "PATHOGENDX", "address": "", "city": "", "state": "AZ", "zip": "", "country": "United States", "approved": true }, "abstract": "With PathogenDx's solution (DetectX-Rv), over the next four months, we will deliver a 25 fold increase in test capacity for the nation without increasing lab-real-estate footprint, without adding endless lines of testing systems that depreciate instantly, upholding the level of accurate testing needed, and a solution that can ‘flex’ to the demands of the market with the different sized SBS plates. What we propose is quadrupling test capacity twice on the same actual test substrate ~ optimizing the same SBS plate from 12 well array slides to 96 wells ultimately to a 384 well format in less than 4 months. Exercising this strategy will deliver 4.15M tests per month, and result in cost savings of 55% and 70% per test. As a comparison, to deploy the same capacity using qRT-PCR technology, it will cost RaDx five times as much in CapEx and three times more per test cost.", "keywords": [ "COVID-19", "Cost Savings", "Exercise", "Performance at work", "Quantitative Reverse Transcriptase PCR", "RADx", "RADx Tech", "Slide", "System", "Technology", "Testing", "Time", "Update", "cost", "variant detection" ], "approved": true } } ], "meta": { "pagination": { "page": 1391, "pages": 1405, "count": 14046 } } }